# Avenge Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avenge-bio

- Industry: Healthcare
- Headquarters: Cambridge, US
- Website: www.avengebio.com
- Total disclosed funding: $46M
- Latest round: Series A (Dec 21, 2021)
- Investors on record: 5

## About

Based in Massachusetts, US, and founded in 2019 by CEO Michael Heffernan and co-founders Dr. Omid Veiseh and Dr. Paul K. Wotton, Avenge Bio is a biotechnology company that develops an immunotherapy platform intended to treat cancer. In January 2022, Avenge Bio raised USD 45 million in series A funding co-led by CAM Capital and Perceptive Advisors, with Longitude Capital and Rock Springs Capital.

Avenge Bio develops the LOCOcyteTM immunotherapy platform for the precise delivery of potent immune effector molecules for the treatment of solid tumors. The LOCOcyteTM platform leverages proprietary engineered cells delivered to the local tumor environment to generate high concentrations of immune effector molecules in proximity to the tumor.

Avenge Bio will use the series A funding to advance its lead program, AVB-001, through the filing of an Investigational New Drug (IND) application and into the clinic for the treatment of metastatic peritoneal cancers, with a primary focus on recurrent and refractory ovarian cancer, and also to continue the rapid development of its pipeline programs.

## Funding rounds

- Series A, Dec 21, 2021, $46M — Pappas Capital, Longitude Capital, CAM Capital, Rock Springs Capital, Perceptive Advisors

## Investors

- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series A
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A
- CAM Capital — Series A
- Rock Springs Capital — Series A
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A